EA018989B1 - Производные 2,4-диоксотиазолидинилиденметана - Google Patents

Производные 2,4-диоксотиазолидинилиденметана Download PDF

Info

Publication number
EA018989B1
EA018989B1 EA201100119A EA201100119A EA018989B1 EA 018989 B1 EA018989 B1 EA 018989B1 EA 201100119 A EA201100119 A EA 201100119A EA 201100119 A EA201100119 A EA 201100119A EA 018989 B1 EA018989 B1 EA 018989B1
Authority
EA
Eurasian Patent Office
Prior art keywords
dione
thiazolidine
benzylidene
thiazolidin
chloro
Prior art date
Application number
EA201100119A
Other languages
English (en)
Russian (ru)
Other versions
EA201100119A1 (ru
Inventor
Лесли Дейкин
Джеймс Эдуард Даулинг
Мишелл Лемб
Джон Рид
Цибинь Су
Сяолань Чжэн
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA018989(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201100119A1 publication Critical patent/EA201100119A1/ru
Publication of EA018989B1 publication Critical patent/EA018989B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EA201100119A 2008-07-02 2009-07-02 Производные 2,4-диоксотиазолидинилиденметана EA018989B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7763908P 2008-07-02 2008-07-02
US18327809P 2009-06-02 2009-06-02
PCT/GB2009/050773 WO2010001169A2 (en) 2008-07-02 2009-07-02 Chemical compounds 251

Publications (2)

Publication Number Publication Date
EA201100119A1 EA201100119A1 (ru) 2011-08-30
EA018989B1 true EA018989B1 (ru) 2013-12-30

Family

ID=41050276

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100119A EA018989B1 (ru) 2008-07-02 2009-07-02 Производные 2,4-диоксотиазолидинилиденметана

Country Status (27)

Country Link
US (2) US8901307B2 (enExample)
EP (1) EP2310010A2 (enExample)
JP (2) JP5261575B2 (enExample)
KR (1) KR20110031367A (enExample)
CN (2) CN102137666B (enExample)
AR (1) AR072791A1 (enExample)
AU (1) AU2009265362B2 (enExample)
BR (1) BRPI0914599A2 (enExample)
CA (1) CA2729557A1 (enExample)
CL (1) CL2010001636A1 (enExample)
CO (1) CO6341555A2 (enExample)
CR (1) CR20110016A (enExample)
DO (1) DOP2010000408A (enExample)
EA (1) EA018989B1 (enExample)
EC (1) ECSP10010735A (enExample)
HN (1) HN2010002786A (enExample)
IL (1) IL210127A0 (enExample)
MX (1) MX2010014233A (enExample)
MY (1) MY155961A (enExample)
NI (1) NI201100007A (enExample)
NZ (1) NZ590859A (enExample)
PE (1) PE20120304A1 (enExample)
SV (1) SV2011003786A (enExample)
TW (1) TWI461423B (enExample)
UY (1) UY31952A (enExample)
WO (1) WO2010001169A2 (enExample)
ZA (1) ZA201100844B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
EP2832727B1 (en) 2012-03-30 2016-09-07 Rohto Pharmaceutical Co., Ltd. Novel benzylidene azolidine derivative or salt thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
JP6378918B2 (ja) * 2013-04-03 2018-08-22 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とするPim阻害剤
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2015046389A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
WO2015046390A1 (ja) * 2013-09-27 2015-04-02 ロート製薬株式会社 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US20170145005A1 (en) * 2014-02-13 2017-05-25 The University Of Tokyo Kinase inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP5857104B2 (ja) * 2014-06-17 2016-02-10 ロート製薬株式会社 ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016100391A1 (en) 2014-12-15 2016-06-23 Prosetta Antiviral, Inc. 2-phenethenyltetrahydro isoquinolines useful as anti-hiv compounds
CN105985298B (zh) * 2015-02-10 2018-02-23 湖南大学 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
CN106032365B (zh) * 2015-03-11 2018-03-23 湖南大学 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
DK3439667T3 (da) 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
IL321754A (en) * 2017-06-30 2025-08-01 Univ California Compositions and methods for modulating hair growth
WO2019090205A1 (en) 2017-11-06 2019-05-09 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
KR20260080448A (ko) 2018-03-30 2026-06-02 인사이트 코포레이션 Jak 억제제를 사용하는 화농성 한선염의 치료
JP7491510B2 (ja) * 2018-04-26 2024-05-28 メディシナル バイオコンバージェンス リサーチ センター mTOR阻害剤としての新規化合物及びその用途
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12649736B2 (en) 2019-12-20 2026-06-09 The Regents Of The University Of California Synthesis of compounds to promote hair growth
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4172159A4 (en) 2020-06-30 2024-01-10 The Regents of the University of California Compositions and methods for modulating hair growth
WO2022086920A1 (en) * 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
CN116354901B (zh) * 2023-04-12 2024-04-26 郑州大学 一种噻唑烷二酮类化合物及其制备方法和应用
EP4746882A1 (en) 2023-07-20 2026-05-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Inhibitors of smndc1 and their therapeutic use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093067A (ja) * 1995-06-16 1997-01-07 Hisamitsu Pharmaceut Co Inc 新規なピペリジン誘導体
EP0976748A1 (en) * 1997-01-31 2000-02-02 Shionogi & Co., Ltd. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US20020120144A1 (en) * 2000-12-22 2002-08-29 Tsutomu Akama Telomerase inhibitors and methods of their use
WO2004093809A2 (en) * 2003-04-18 2004-11-04 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
WO2006069186A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
NO305987B1 (no) 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ID29875A (id) * 1999-07-01 2001-10-18 Geron Corp Cs Penghambat-penghambat telomerase dan metode penggunaannya
TW593293B (en) * 1999-08-23 2004-06-21 Kyorin Seiyaku Kk Substituted benzylthiazolidine-2,4-dione derivatives
US6730687B1 (en) * 1999-08-23 2004-05-04 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2, 4-dione derivatives
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH093067A (ja) * 1995-06-16 1997-01-07 Hisamitsu Pharmaceut Co Inc 新規なピペリジン誘導体
EP0976748A1 (en) * 1997-01-31 2000-02-02 Shionogi & Co., Ltd. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
WO2001034133A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US20020120144A1 (en) * 2000-12-22 2002-08-29 Tsutomu Akama Telomerase inhibitors and methods of their use
WO2004093809A2 (en) * 2003-04-18 2004-11-04 Incyte San Diego Incorporated Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
WO2006069186A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OTTANA R. ET AL.: "In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidi nones. Part I" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB LNKD-DOI: 10.1016/J. BMCL. 2005.05.093, vol. 15, no. 17, 1 September 2005 (2005-09-01), pages 3930-3933, XP025314117 ISSN: 0960-894X [retrieved on 2005-09-01] the whole document page 3931; figure l, compound 4 *
XIA ZUPING ET AL.: "Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases". JOURNAL OF MEDICINAL CHEMISTRY 8 JAN 2009 LNKD-PUBMED: 19072652, vol. 52, no. 1, 8 January 2009 (2009-01-08), pages 74-86, XP002584626 ISSN: 1520-4804 the whole document page 78; table 3; compounds 6a, 7a *

Also Published As

Publication number Publication date
NZ590859A (en) 2012-08-31
TW201004949A (en) 2010-02-01
UY31952A (es) 2010-01-29
CN102137666A (zh) 2011-07-27
EP2310010A2 (en) 2011-04-20
US20110218182A1 (en) 2011-09-08
ZA201100844B (en) 2011-10-26
NI201100007A (es) 2011-12-15
JP5261575B2 (ja) 2013-08-14
KR20110031367A (ko) 2011-03-25
MY155961A (en) 2015-12-31
PE20120304A1 (es) 2012-04-22
TWI461423B (zh) 2014-11-21
JP2013139459A (ja) 2013-07-18
CO6341555A2 (es) 2011-11-21
JP2011526616A (ja) 2011-10-13
MX2010014233A (es) 2011-03-25
US8901307B2 (en) 2014-12-02
CN102137666B (zh) 2014-03-12
AU2009265362B2 (en) 2012-07-19
HN2010002786A (es) 2013-01-28
WO2010001169A2 (en) 2010-01-07
EA201100119A1 (ru) 2011-08-30
WO2010001169A3 (en) 2010-08-05
AR072791A1 (es) 2010-09-22
SV2011003786A (es) 2011-05-13
IL210127A0 (en) 2011-02-28
CA2729557A1 (en) 2010-01-07
CR20110016A (es) 2011-03-11
BRPI0914599A2 (pt) 2017-06-06
US20150051185A1 (en) 2015-02-19
ECSP10010735A (es) 2011-01-31
CL2010001636A1 (es) 2011-07-15
AU2009265362A1 (en) 2010-01-07
DOP2010000408A (es) 2011-02-28
CN103804371A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
US8901307B2 (en) Chemical compounds 251
RU2525389C2 (ru) Соединения, которые являются ингибиторами erk
KR101014525B1 (ko) 신규 화합물
EP2547664B1 (de) Morpholinylchinazoline
KR101084871B1 (ko) 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
RU2422449C2 (ru) Фармацевтические соединения
EP2468717B1 (en) Heterocyclic Amide Compounds Useful as Kinase Inhibitors
US8188101B2 (en) Dihydropyridopyrimidines for the treatment of AB-related pathologies
JP2021529740A (ja) サイクリン依存性キナーゼの阻害剤
JP2011507908A (ja) ベンゾフロピリミジノン
KR20190034620A (ko) 피페리딘 cxcr7 수용체 조절제
US20040097502A1 (en) Pyrazoles as tgf inhibitors
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
KR102466810B1 (ko) 포유류 티로신 키나제 ror1 활성의 저해제로서 유용한 2-페닐이미다조[4,5-b]피리딘-7-아민 유도체
EP3587411B1 (en) 1-(alpha-methylbenzyl)-5-(piperidinomethyl)imidazole derivatives and uses thereof for improving the pharmacokinetics of a drug
AU616708B2 (en) 4-heteropentacyclic-4-{n-(phenyl)amido}piperidine derivatives and pharmaceutical compositions and method employing such compounds
JP2008501672A (ja) ケモカイン受容体アンタゴニストとしてのチアゾール誘導体
KR101730205B1 (ko) 신규 (헤테로사이클/테트라히드로피리딘)-(피페라지닐)-1-알카논 및 (헤테로사이클/디히드로피롤리딘)-(피페라지닐)-1-알카논유도체, 및 p75 억제제로서의 그의 용도
US8318749B2 (en) Quinazoline derivatives as NK3 receptor antagonists
KR20250127267A (ko) 튜불린 중합 억제제

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ